Difference between revisions of "Durvalumab (Imfinzi)"
(Created page with "'''in clinical trials''' ==General information== Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating...") |
m (Jwarner moved page Durvalumab (MEDI4736) to Durvalumab (Imfinzi)) |
(No difference)
| |
Revision as of 19:47, 1 May 2017
in clinical trials
General information
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Durvalumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, durvalumab stimulates immune responses, including anti-tumor immune effects. Durvalumab is being investigated for potential use as monotherapy or in combination with tremelimumab (ticilimumab) in non-small cell lung cancer, head and neck cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatocellular carcinoma, and blood cancers.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.